ChlVPP chemotherapy in advanced Hodgkin's disease

J. J. McKendrick; G. M. Mead; J. Sweetenham; D. H. Jones; C. J. Williams; R. Ryall; J. M.A. Whitehouse

doi:10.1016/0277-5379(89)90270-8

ChlVPP chemotherapy in advanced Hodgkin's disease

J. J. McKendrick, G. M. Mead, J. Sweetenham, D. H. Jones, C. J. Williams, R. Ryall, J. M.A. Whitehouse

Research output: Contribution to journal › Article › peer-review

22 Scopus citations

Abstract

Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.

Original language	English (US)
Pages (from-to)	557-561
Number of pages	5
Journal	European Journal of Cancer and Clinical Oncology
Volume	25
Issue number	3
DOIs	https://doi.org/10.1016/0277-5379(89)90270-8
State	Published - Mar 1989
Externally published	Yes

ASJC Scopus subject areas

Oncology

Access to Document

10.1016/0277-5379(89)90270-8

Cite this

@article{1ef507f55f344d70be11db3dcb2b6a47,

title = "ChlVPP chemotherapy in advanced Hodgkin's disease",

abstract = "Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.",

author = "McKendrick, {J. J.} and Mead, {G. M.} and J. Sweetenham and Jones, {D. H.} and Williams, {C. J.} and R. Ryall and Whitehouse, {J. M.A.}",

note = "Funding Information: Acknowledgements--The authors wish to thank the Data Unit of the CRC Wessex Regional Oncology Unit for assistance in compiling this information, the Cancer Research Campaign for financial support, and clinicians in the Wessex Region for referring patients to the Unit. Secretarial assistance from Miss Beryl Addison and Mrs Jill Baston is greatly appreciated.",

year = "1989",

month = mar,

doi = "10.1016/0277-5379(89)90270-8",

language = "English (US)",

volume = "25",

pages = "557--561",

journal = "European Journal of Cancer and Clinical Oncology",

issn = "0277-5379",

publisher = "Pergamon Press",

number = "3",

}

TY - JOUR

T1 - ChlVPP chemotherapy in advanced Hodgkin's disease

AU - McKendrick, J. J.

AU - Mead, G. M.

AU - Sweetenham, J.

AU - Jones, D. H.

AU - Williams, C. J.

AU - Ryall, R.

AU - Whitehouse, J. M.A.

N1 - Funding Information: Acknowledgements--The authors wish to thank the Data Unit of the CRC Wessex Regional Oncology Unit for assistance in compiling this information, the Cancer Research Campaign for financial support, and clinicians in the Wessex Region for referring patients to the Unit. Secretarial assistance from Miss Beryl Addison and Mrs Jill Baston is greatly appreciated.

PY - 1989/3

Y1 - 1989/3

N2 - Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.

AB - Between March 1978 and January 1987 54 patients with advanced Hodgkin's disease (HD) or relapse following radiotherapy (RT) for Hodgkin's disease have been treated with combination chemotherapy consisting of chlorambucil, vinblastine, procarbazine and prednisolone (ChlVPP). A subgroup of five patients with bulky mediastinal disease received mantle RT in addition to ChlVPP chemotherapy. Forty-two patients (77.8%) entered complete remission with 33 (61.0%) remaining in unmaintained remission and 44 (81.5%) alive at a median follow up of 51 months (range: 22-103). The treatment was generally well tolerated with minimal toxicity. ChlVPP is effective first-line treatment for Hodgkin's disease with results which may be comparable to those achieved for MOPP but with significantly less toxicity.

UR - http://www.scopus.com/inward/record.url?scp=0024517841&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024517841&partnerID=8YFLogxK

U2 - 10.1016/0277-5379(89)90270-8

DO - 10.1016/0277-5379(89)90270-8

M3 - Article

C2 - 2703008

AN - SCOPUS:0024517841

SN - 0277-5379

VL - 25

SP - 557

EP - 561

JO - European Journal of Cancer and Clinical Oncology

JF - European Journal of Cancer and Clinical Oncology

IS - 3

ER -

ChlVPP chemotherapy in advanced Hodgkin's disease

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this